Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminogen (amino acids) provide substrate for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; phosphate is essential for cellular metabolism and buffering.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion; typical adult dose: 1-1.5 g amino acids/kg/day, with dextrose providing 10% final concentration. Adjusted to meet protein and caloric needs.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
Amino acids have a terminal elimination half-life of approximately 1.5–2 hours in healthy adults, reflecting rapid metabolic clearance. In renal impairment, half-life may be prolonged due to accumulation of nitrogenous waste.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
The components of AMINOSYN II (amino acids) and dextrose are primarily metabolized; excess nitrogen is excreted renally as urea. Dextrose is completely oxidized. Electrolytes are excreted mainly renally. Biliary/fecal elimination is negligible for amino acids and dextrose (<2%).
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution